Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
363 studies found for:    Chlormethine
Show Display Options
Rank Status Study
21 Recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Conditions: HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
22 Not yet recruiting Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Tacrolimus
23 Recruiting Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation
Condition: Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation--CD34 HSCT;   Procedure: Peripheral Blood Stem Cell Transplantation--AHSCT;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation;   Biological: Tetanus Toxoid Vaccine;   Biological: Therapeutic Autologous Lymphocytes;   Biological: Trivalent Influenza Vaccine;   Biological: XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
24 Withdrawn Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Conditions: Acute Myeloid Leukemia in Remission;   Primary Myelofibrosis;   Primary Myelofibrosis, Prefibrotic Stage;   Secondary Acute Myeloid Leukemia;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
25 Recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Biological: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
26 Not yet recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
27 Recruiting JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
28 Recruiting Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Condition: Unilateral Retinoblastoma
Intervention: Drug: Melphalan
29 Recruiting Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
30 Suspended Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carfilzomib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan
31 Suspended Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Drug: Tacrolimus
32 Active, not recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Alemtuzumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tacrolimus;   Drug: Vincristine Sulfate
33 Terminated RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Gamma-Secretase Inhibitor RO4929097;   Procedure: Hematopoietic Stem Cell Mobilization;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan
34 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
35 Active, not recruiting Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Diffuse Large B-Cell Lymphoma;   B-Cell Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin Lymphoma;   T-Cell Non-Hodgkin Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Bortezomib;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Rituximab;   Drug: Vorinostat
36 Recruiting Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Conditions: Adult Central Nervous System Germ Cell Tumor;   Adult Ependymoblastoma;   Adult Medulloblastoma;   Adult Pineoblastoma;   Adult Supratentorial Primitive Neuroectodermal Tumor;   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Ependymoblastoma;   Medulloepithelioma;   Ototoxicity;   Recurrent Adult Brain Neoplasm;   Recurrent Childhood Central Nervous System Embryonal Neoplasm;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: Carboplatin;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sodium Thiosulfate
37 Active, not recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Condition: Refractory Plasma Cell Myeloma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Bortezomib;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Syngeneic Bone Marrow Transplantation;   Radiation: Total-Body Irradiation
38 Recruiting Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Condition: Autoimmune Disease
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
39 Active, not recruiting Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Filgrastim;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Liposome
40 Recruiting Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
Interventions: Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years